Article
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
Hematological oncology - 1 Aug 2020
Chien Sheng-Hsuan, Liu Hsueng-Mei, Chen Po-Ming, Ko Po-Shen, Lin Jeong-Shi, Chen Ying-Ju, Lee Li-Hsuan, Hsiao Liang-Tsai, Chiou Tzeon-Jye, Gau Jyh-Pyng, Yang Muh-Hwa, Liu Chun-Yu
Abstract excerpt
BCR-ABL mutations are associated with resistance to tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome-positive leukaemia. The emergence of these mutations in the era of second-generation TKIs, such as dasatinib and nilotinib, remains an evolving field. We conducted a retrospective study to quantitatively characterize the BCR-ABL transcript and mutation status during treatment with first-generation and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.